1. Reactogenicity and Immunogenicity of a Protein-Conjugated Pneumococcal Oligosaccharide Vaccine in Older Adults
- Author
-
Douglas C. Powers, Edwin L. Anderson, ChrisAnna M. Mink, and Kathleen R. Lottenbach
- Subjects
Male ,Serotype ,Time Factors ,Oligosaccharides ,medicine.disease_cause ,Streptococcus pneumoniae ,medicine ,Humans ,Immunology and Allergy ,Bacterial Capsules ,Aged ,Reactogenicity ,biology ,business.industry ,Corynebacterium diphtheriae ,Immunogenicity ,Middle Aged ,Antibodies, Bacterial ,Pneumococcal polysaccharide vaccine ,Virology ,Vaccination ,Infectious Diseases ,Pneumococcal vaccine ,Immunoglobulin G ,Bacterial Vaccines ,Immunology ,biology.protein ,Female ,Antibody ,business - Abstract
Healthy adults > or = 50 years old were immunized with either pentavalent Corynebacterium diphtheriae C7 (beta197) cross-reactive material (CRM197) protein-conjugated pneumococcal vaccine (CV) containing 10 microgram each of capsular oligosaccharides from serotypes 6B, 14, 18C, 19F, and 23F or with licensed (23-valent, 25 microgram/serotype) pneumococcal polysaccharide vaccine (PV). Adverse reactions, predominantly local in nature, occurred in 20 of 23 CV recipients versus 13 of 23 PV recipients (P
- Published
- 1996